Evidence map›Paper›PMID 25637044›Full record

Trial reportHeart and vessels2016

Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCI.

Kun Xing, Xianghua Fu, Yanbo Wang, Wei Li, Xinshun Gu, Guozhen Hao, Qing Miao, Shiqiang Li, Yunfa Jiang, Weize Fan and 1 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 5 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Contrast-Induced Acute Kidney Injury: Review and Practical Update.Clinical Medicine Insights. Cardiology · 2019
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kun XingDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xianghua FuDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. fuxh99@126.com.
Yanbo WangDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Wei LiDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xinshun GuDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Guozhen HaoDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Qing MiaoDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Shiqiang LiDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yunfa JiangDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Weize FanDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Wei GengDepartment of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Hebei Medical University · CNSecond Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to investigate the effect of recombinant human brain natriuretic peptide (rhBNP) on renal function and contrast-induced nephropathy (CIN) incidence in ST-segment elevation myocardial infarction and heart failure (STEMI-HF) patients with mild renal insufficiency undergoing primary percutaneous coronary intervention (PCI). A total of 116 participants were randomized into rhBNP (rhBNP, n = 57) and nitroglycerin group (NIT, n = 59), receiving intravenous rhBNP or nitroglycerin from admission to 72 h after PCI. Renal function was assessed by serum creatinine (SCr), estimated glomerular filtration rate (eGFR), Cystatin-C (Cys-C) and β2-microglobulin before and after primary PCI, and calculated the incidence of CIN within 72 h after PCI. There were no significant differences in SCr, eGFR and β2-microglobulin between the two groups (P > 0.05, respectively). Compared with the NIT group, the total urinary volume within 72 h was higher while the level of Cys-C at 24 and 72 h after PCI was lower in the rhBNP group. rhBNP was associated with a decline in the incidence of CIN (12.28 vs. 28.81 %, P < 0.05). No differences were detected in mortality and re-hospitalization in 3 months between the two groups. The incidence of renal injury was not different between rhBNP and nitroglycerin in STEMI-HF patients with mild renal insufficiency. However, infusion of rhBNP was associated with a decline in incidence of CIN.

Indexed as

CreatinineElectrocardiographyFemaleFollow-Up StudiesGlomerular Filtration RateHeart FailureHumansInfusions, IntravenousMaleMiddle AgedNatriuretic AgentsNatriuretic Peptide, BrainPercutaneous Coronary InterventionPrognosisProspective StudiesRecombinant ProteinsCreatinineNatriuretic AgentsNatriuretic Peptide, BrainRecombinant ProteinsAcute myocardial infarctionCystatin-CMild renal insufficiencyPercutaneous coronary interventionrhBNPSerum creatinine

Identifiers

PMID25637044
OpenAlexW2058245391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.